Delong Liu

Summary

Affiliation: New York Medical College
Country: USA

Publications

  1. ncbi request reprint The phenylhexyl isothiocyanate induces apoptosis and inhibits leukemia cell growth in vivo
    Lulu Lu
    Department of Medicine, New York Medical College, Valhalla, NY 10595, USA
    Oncol Rep 16:1363-7. 2006
  2. pmc t(8;14;18): a 3-way chromosome translocation in two patients with Burkitt's lymphoma/leukemia
    Delong Liu
    Division of Oncology Hematology, New York Medical College and Westchester Medical Center, Valhalla, NY 10595, USA
    Mol Cancer 6:35. 2007
  3. doi request reprint Phosphatidylinositol 3-kinase (PI3K) inhibitors as cancer therapeutics
    Akintunde Akinleye
    Division of Hematology Oncology, Department of Medicine, New York Medical College and Westchester Medical Center, Valhalla, NY 10595, USA
    J Hematol Oncol 6:88. 2013
  4. doi request reprint STAT inhibitors for cancer therapy
    Muhammad Furqan
    Department of Medicine, New York Medical College and Westchester Medical Center, Valhalla, NY 10595, USA
    J Hematol Oncol 6:90. 2013
  5. pmc Publish, not perish: Introducing Experimental Hematology & Oncology
    Zihai Li
    Department of Microbiology and Immunology, Medical University of South Carolina, Charlston, SC 29425, USA
    Exp Hematol Oncol 1:1. 2012
  6. pmc B-Raf and the inhibitors: from bench to bedside
    Tiangui Huang
    Department of Pathology, Westchester Medical Center and New York Medical College, Valhalla, NY 10595, USA
    J Hematol Oncol 6:30. 2013
  7. pmc MEK and the inhibitors: from bench to bedside
    Akintunde Akinleye
    Department of Medicine, Westchester Medical Center and New York Medical College, Valhalla, NY 10595, USA
    J Hematol Oncol 6:27. 2013
  8. pmc CD19: a biomarker for B cell development, lymphoma diagnosis and therapy
    Kemeng Wang
    Division of Hematology and Oncology, Department of Medicine, New York Medical College and Westchester Medical Center, Valhalla, NY 10595, USA
    Exp Hematol Oncol 1:36. 2012
  9. pmc Comparison of safety and toxicity of liposomal doxorubicin vs. conventional anthracyclines: a meta-analysis
    Shamudheen M Rafiyath
    Division of Hematology and Oncology, New York Medical College and Westchester Medical Center, Valhalla, NY 10595, USA
    Exp Hematol Oncol 1:10. 2012
  10. pmc Current management and prognostic features for gastrointestinal stromal tumor (GIST)
    Gurpreet Lamba
    Division of Oncology Hematology, New York Medical College and Westchester Medical Center, Valhalla, NY, 10595, USA
    Exp Hematol Oncol 1:14. 2012

Collaborators

  • Karen Seiter
  • Shundong Cang
  • Gurpreet Lamba
  • Guoqing Wei
  • Quanyi Lu
  • E L Chung
  • Qian Sun
  • Eunice S Wang
  • Roger M Lyons
  • Jian Zhuge
  • Feng Gao
  • Baoan Chen
  • Xiongpeng Zhu
  • Wei Dai
  • Claudio Sandoval
  • Robert B Nadelman
  • Wenhong Cao
  • Zhen qi Liu
  • Akintunde Akinleye
  • Muhammad Furqan
  • Nikhil Mukhi
  • Tauseef Ahmed
  • Jiahuai Tan
  • Xudong Ma
  • Byung Lee
  • J W Chiao
  • Tiangui Huang
  • Yamei Chen
  • Yongping Song
  • Kemeng Wang
  • Jiangning Zhao
  • Shamudheen M Rafiyath
  • Zihai Li
  • Longgui Wang
  • Jen Wei Chiao
  • Liyun Xiao
  • Nasir Ahmed
  • Arunabh Sekhri
  • Sivamurthy Kyathari
  • Samir Patel
  • Yan Xiong
  • Lu Lu Lü
  • Lulu Lu
  • Woondong Jeong
  • Muhammad Arshad
  • Gita Ramaswamy
  • Fung Lung Chung
  • Pavan Ravella
  • Minghao Zhong
  • Parthu Avvaru
  • Michael Karsy
  • Varun Mittal
  • Mohammad Rasul
  • Chung Tsen Hsueh
  • Zhenshu Xu
  • Yuehua Ma
  • Ruiji Zhen
  • Yiqun Huang
  • Richard L Petrillo
  • Thomas Mathews
  • Suneeta Primanneni
  • Muhammad Rasul
  • Kuo Chao
  • Jie An
  • Jacques Robidoux
  • Edgar Lupo
  • Philip Caron
  • Hui Yu Liu
  • Qu Fan Collins
  • Yong Jun Liu
  • Shao Guang Yang
  • Xin Wang
  • Zhi Zhe Chen
  • Zhi Bo Han
  • Zhen Shu Xu
  • Yong Xin Lu
  • Jingyang Feng
  • Wei Gong
  • Anastasia Beklemishev
  • Qin Jun Zhao
  • Yuqiang Fang
  • Anastasia Beklemisheva
  • Zhong Chao Han
  • Har Chi Lau
  • Jaroslaw Bilaniuk
  • Anila Qureshi
  • James Strauchen
  • Asawari Patil
  • Beth Breakstone
  • Theodore Rafael

Detail Information

Publications45

  1. ncbi request reprint The phenylhexyl isothiocyanate induces apoptosis and inhibits leukemia cell growth in vivo
    Lulu Lu
    Department of Medicine, New York Medical College, Valhalla, NY 10595, USA
    Oncol Rep 16:1363-7. 2006
    ..In conclusion, PHI induced apoptosis and inhibited the growth of xenografts by targeting the cell cycle regulators. PHI induced selective apoptosis effects in the rapidly growing tumor cells but not in the normal tissues...
  2. pmc t(8;14;18): a 3-way chromosome translocation in two patients with Burkitt's lymphoma/leukemia
    Delong Liu
    Division of Oncology Hematology, New York Medical College and Westchester Medical Center, Valhalla, NY 10595, USA
    Mol Cancer 6:35. 2007
    ..Dual translocation of t(8;14) (c-myc) and t(14;18) (bcl-2) was reported to be associated with extremely poor prognosis. This study reports a novel t(8;14;18) triple translocation in two patients with Burkitt's lymphoma...
  3. doi request reprint Phosphatidylinositol 3-kinase (PI3K) inhibitors as cancer therapeutics
    Akintunde Akinleye
    Division of Hematology Oncology, Department of Medicine, New York Medical College and Westchester Medical Center, Valhalla, NY 10595, USA
    J Hematol Oncol 6:88. 2013
    ..In this review, we summarized the major molecules of PI3K signaling pathway, and discussed the preclinical models and clinical trials of potent small-molecule PI3K inhibitors. ..
  4. doi request reprint STAT inhibitors for cancer therapy
    Muhammad Furqan
    Department of Medicine, New York Medical College and Westchester Medical Center, Valhalla, NY 10595, USA
    J Hematol Oncol 6:90. 2013
    ..Inhibitors targeting STAT3 and STAT5 have been developed. These included peptidomimetics, small molecule inhibitors and oligonucleotides. This review summarized advances in preclinical and clinical development of these compounds. ..
  5. pmc Publish, not perish: Introducing Experimental Hematology & Oncology
    Zihai Li
    Department of Microbiology and Immunology, Medical University of South Carolina, Charlston, SC 29425, USA
    Exp Hematol Oncol 1:1. 2012
    ..The focus of the peer-review mechanism for eHO will be on the technical merit of the study and not on demanding a long list of additional experiments that hinders rapid information dissemination...
  6. pmc B-Raf and the inhibitors: from bench to bedside
    Tiangui Huang
    Department of Pathology, Westchester Medical Center and New York Medical College, Valhalla, NY 10595, USA
    J Hematol Oncol 6:30. 2013
    ..This review also discussed the current understanding of B-Raf signaling mechanism, methods of mutation detection, treatment strategies as well as potential methods of overcoming therapeutic resistance...
  7. pmc MEK and the inhibitors: from bench to bedside
    Akintunde Akinleye
    Department of Medicine, Westchester Medical Center and New York Medical College, Valhalla, NY 10595, USA
    J Hematol Oncol 6:27. 2013
    ..This review also summarized new MEK inhibitors in clinical development, including pimasertib, refametinib, PD-0325901, TAK733, MEK162 (ARRY 438162), RO5126766, WX-554, RO4987655 (CH4987655), GDC-0973 (XL518), and AZD8330...
  8. pmc CD19: a biomarker for B cell development, lymphoma diagnosis and therapy
    Kemeng Wang
    Division of Hematology and Oncology, Department of Medicine, New York Medical College and Westchester Medical Center, Valhalla, NY 10595, USA
    Exp Hematol Oncol 1:36. 2012
    ..This review also summarized latest clinical development of CD19 antibodies, anti-B4-bR (an immunotoxin conjugate), blinatumomab (BiTE), and SAR3419 (huB4-DM4), a novel antibody-drug conjugate...
  9. pmc Comparison of safety and toxicity of liposomal doxorubicin vs. conventional anthracyclines: a meta-analysis
    Shamudheen M Rafiyath
    Division of Hematology and Oncology, New York Medical College and Westchester Medical Center, Valhalla, NY 10595, USA
    Exp Hematol Oncol 1:10. 2012
    ..abstract:..
  10. pmc Current management and prognostic features for gastrointestinal stromal tumor (GIST)
    Gurpreet Lamba
    Division of Oncology Hematology, New York Medical College and Westchester Medical Center, Valhalla, NY, 10595, USA
    Exp Hematol Oncol 1:14. 2012
    ..Indications for neoadjuvant and adjuvant therapy along with duration of therapy are also explained. A brief discussion of latest biomarkers and updates from recent meetings is also provided...
  11. pmc Novel CD20 monoclonal antibodies for lymphoma therapy
    Shundong Cang
    Department of Oncology, People s Hospital, Henan Province, China
    J Hematol Oncol 5:64. 2012
    ....
  12. pmc Rituximab and new regimens for indolent lymphoma: a brief update from 2012 ASCO Annual Meeting
    Jiangning Zhao
    Department of Hematology, Zhongshan Hospital of Xiamen University, Xiamen 361004, China
    Cancer Cell Int 12:38. 2012
    ..In this review, new combination regimens reported at 2012 ASCO annual meeting were evaluated for frontline and salvage therapy of indolent lymphoma...
  13. pmc A meta-analysis of CAG (cytarabine, aclarubicin, G-CSF) regimen for the treatment of 1029 patients with acute myeloid leukemia and myelodysplastic syndrome
    Guoqing Wei
    Bone Marrow Transplantation Center, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
    J Hematol Oncol 4:46. 2011
    ..Randomized controlled trials are strongly recommended to evaluate its efficacy and safety in comparison with the current standard treatment...
  14. pmc First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib
    Guoqing Wei
    Bone Marrow Transplantation Center, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, PR China
    J Hematol Oncol 3:47. 2010
    ..This review compares and contrasts the three FDA approved first line TKI agents...
  15. ncbi request reprint Sweet's syndrome with CML cell infiltration of the skin in a patient with chronic-phase CML while taking Imatinib Mesylate
    Delong Liu
    New York Medical College and Zalmen A Arlin Cancer Institute, Room 250, Munger Pavilion, Valhalla, NY 10595, USA
    Leuk Res 28:S61-3. 2004
    ....
  16. doi request reprint t(3;9;22) 3-way chromosome translocation in chronic myeloid leukemia is associated with poor prognosis
    Jiahuai Tan
    Department of Medicine, Mount Vernon Hospital, Mount Vernon, NY, USA
    Cancer Invest 27:718-22. 2009
    ..A review of the literature appears to indicate that CML patients with this translocation tend to have an aggressive course and poor outcome. Additional 3-way chromosome translocations associated with CML are also reviewed...
  17. ncbi request reprint Long-term follow-up of high-dose mitoxantrone-based induction therapy for patients with newly-diagnosed acute myelogenous leukemia. Twelve year results from a single institution
    Karen Seiter
    Zalmen A Arlin Cancer Institute and New York Medical College, New York 10595, USA
    Leuk Lymphoma 47:425-32. 2006
    ..Use of a once-daily cytarabine regimen resulted in almost no neurotoxicity and allowed for administration of consolidation in the outpatient setting...
  18. pmc Recent advances and novel agents for gastrointestinal stromal tumor (GIST)
    Gurpreet Lamba
    Division of Oncology Hematology, New York Medical College and Westchester Medical Center, Valhalla, NY 10595, USA
    J Hematol Oncol 5:21. 2012
    ..A series of investigations and trials are underway to develop novel and effective ways to treat patients with GIST. In this review, we discuss the highlights of recent advances and novel agents for GIST therapy...
  19. pmc Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents
    Jiahuai Tan
    Department of Medicine, The Mount Vernon Hospital, Mount Vernon, NY 10550, USA
    J Hematol Oncol 3:5. 2010
    ..This review focuses on recent development in clinical trials testing HDAC inhibitors as anti-tumor agents...
  20. pmc P-loop mutations and novel therapeutic approaches for imatinib failures in chronic myeloid leukemia
    Shundong Cang
    Division of Hematology Oncology, New York Medical College, Valhalla, NY 10595, USA
    J Hematol Oncol 1:15. 2008
    ..This communication reviews the clinical importance of P-loop mutations and the efficacy of the currently available TKIs against them...
  21. pmc Phenylhexyl isothiocyanate has dual function as histone deacetylase inhibitor and hypomethylating agent and can inhibit myeloma cell growth by targeting critical pathways
    Quanyi Lu
    Division of Hematology Oncology, New York Medical College, Valhalla, NY 10595, USA
    J Hematol Oncol 1:6. 2008
    ..We conclude that PHI has dual epigenetic effects on p16 hypomethylation and histone hyperacetylation in myeloma cells and targets several critical processes of myeloma proliferation...
  22. ncbi request reprint Phenylhexyl isothiocyanate inhibits histone deacetylases and remodels chromatins to induce growth arrest in human leukemia cells
    Xudong Ma
    Department of Medicine, New York Medical College, Valhalla, NY 10595, USA
    Int J Oncol 28:1287-93. 2006
    ..The results revealed a potential selective effect of isothiocyanates to inhibit the growth of malignant cells...
  23. ncbi request reprint Side effects related to cancer treatment: CASE 2. Splenic rupture following pegfilgrastim
    Muhammad Arshad
    Department of Medicine, New York Medical College, Valhalla, NY, USA
    J Clin Oncol 23:8533-4. 2005
  24. doi request reprint Deficient histone acetylation in acute leukemia and the correction by an isothiocyanate
    Liyun Xiao
    Department of Hematology, Zhangzhou Affiliated Hospital of Fujian Medical University, Zhangzhou, China
    Acta Haematol 123:71-6. 2010
    ....
  25. pmc Ibrutinib and novel BTK inhibitors in clinical development
    Akintunde Akinleye
    Division of Hematology Oncology, Department of Medicine, New York Medical College, Valhalla, New York 10595, USA
    J Hematol Oncol 6:59. 2013
    ....
  26. ncbi request reprint Evaluation of temozolomide in patients with myelodysplastic syndrome
    Karen Seiter
    Zalmen A Arlin Cancer Institute, Department of Medicine, New York Medical College, Valhalla, New York, USA
    Leuk Lymphoma 45:1209-14. 2004
    ..An unusual finding was the development of leukocytoclastic vasculitis in 4 patients. There were no formal responses to therapy. The current schedule of temozolomide is not efficacious in patients with myelodysplastic syndrome...
  27. doi request reprint Prospective evaluation of 2009 H1N1 influenza A in patients admitted with fever to an oncology unit
    Karen Seiter
    Department of Medicine, New York Medical College, Valhalla, New York 10595, USA
    Infect Control Hosp Epidemiol 32:815-7. 2011
    ..However, early antiviral intervention could have contributed to a favorable outcome...
  28. pmc New clinical developments in histone deacetylase inhibitors for epigenetic therapy of cancer
    Shundong Cang
    Division of Hematology Oncology, New York Medical College, Valhalla, NY 10595, USA
    J Hematol Oncol 2:22. 2009
    ..In this review we summarize novel histone deacetylase inhibitors and new regimens from clinical trials for epigenetic therapy of cancer...
  29. pmc Current management and novel agents for malignant melanoma
    Byung Lee
    Division of Hematology and Oncology, New York Medical College and Westchester Medical Center, Valhalla, New York 10595, USA
    J Hematol Oncol 5:3. 2012
    ..This review will also update on the development of novel agents, including tyrosine kinase inhibitors and adoptive cellular therapy...
  30. doi request reprint Very late relapse of chronic myelogenous leukemia after allogeneic bone marrow transplantation
    Arunabh Sekhri
    Department of Medicine, New York Medical College, Valhalla, NY 10595, USA
    Leuk Res 33:1291-3. 2009
    ..Currently we present two patients who relapsed 16 and 24 years after allogeneic bone marrow transplantation, respectively. These patients emphasize the need for long term follow-up of such patients...
  31. ncbi request reprint Severe toxicity following induction chemotherapy for acute myelogenous leukemia in a patient with Werner's syndrome
    Karen Seiter
    Zalmen A Arlin Cancer Institute, New York Medical College, Valhalla, NY 10595, USA
    Leuk Lymphoma 46:1091-5. 2005
    ..We propose that lack of WRN resulted in increased sensitivity of the patient's cells to the toxicity of chemotherapy...
  32. pmc A randomized, double-blind, placebo-controlled phase 2 study evaluating the efficacy and safety of romiplostim treatment of patients with low or intermediate-1 risk myelodysplastic syndrome receiving lenalidomide
    Eunice S Wang
    Leukemia Service, Department of Medicine, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263, USA
    J Hematol Oncol 5:71. 2012
    ..This study evaluated the safety and tolerability of the thrombopoietin mimetic romiplostim and its effects on the incidence of clinically significant thrombocytopenic events (CSTEs) in lower risk MDS patients receiving lenalidomide...
  33. pmc Novel agents and regimens for acute myeloid leukemia: 2009 ASH annual meeting highlights
    Xiongpeng Zhu
    Department of Hematology, First Hospital of Quanzhou Affiliated to Fujian Medical University, Quanzhou, 362000, China
    J Hematol Oncol 3:17. 2010
    ..This review also summarizes the updates of the clinical trials on novel agents including voreloxin, AS1413, behenoylara-C, ARRY520, ribavirin, AZD1152, AZD6244, and terameprocol (EM-1421) from the 2009 ASH annual meeting...
  34. ncbi request reprint PET scan-positive cat scratch disease in a patient with T cell lymphoblastic lymphoma
    Woondong Jeong
    Arlin Cancer Institute and New York Medical College, Valhalla, NY 10595, USA
    Leuk Res 29:591-4. 2005
    ..This was pathologically proven to be cat scratch disease. This case suggests that in the immunocompromised patients who had history of lymphoma, infectious etiology should be ruled out for PET scan-positive lymphadenopathy...
  35. pmc Reversal in multidrug resistance by magnetic nanoparticle of Fe3O4 loaded with adriamycin and tetrandrine in K562/A02 leukemic cells
    Baoan Chen
    Department of Hematology, Zhongda Hospital, Southeast University, Nanjing, China
    Int J Nanomedicine 3:277-86. 2008
    ..We propose that Fe3O4-MNPs loaded with ADM and Tet probably have synergetic effect on reversal in multidrug resistance...
  36. ncbi request reprint Phase I study of temozolomide in relapsed/refractory acute leukemia
    Karen Seiter
    Department of Medicine, Zalmen A Arlin Cancer Institute, Munger Pavilion Room 250, New York Medical College, Valhalla, NY 10595, USA
    J Clin Oncol 20:3249-53. 2002
    ..To determine the dose-limiting toxicity and maximum-tolerated dose of temozolomide in patients with acute leukemia...
  37. ncbi request reprint Ingestion of an isothiocyanate metabolite from cruciferous vegetables inhibits growth of human prostate cancer cell xenografts by apoptosis and cell cycle arrest
    Jen Wei Chiao
    Department of Medicine, New York Medical College, Valhalla, NY 10595, USA
    Carcinogenesis 25:1403-8. 2004
    ..PEITC-NAC may prevent initiation of carcinogenesis and modulate the post-initiation phase by targeting cell cycle regulators and apoptosis induction...
  38. ncbi request reprint Clinical advances in hypomethylating agents targeting epigenetic pathways
    S Cang
    Department of Oncology, People s Hospital, Henan Province, Zhengzhou, China
    Curr Cancer Drug Targets 10:539-45. 2010
    ..In this review we summarize recent clinical developments on novel hypomethylating agents and new regimens from clinical trials for epigenetic therapy of cancer...
  39. ncbi request reprint Targeting cell cycle machinery as a molecular mechanism of sulforaphane in prostate cancer prevention
    Longgui Wang
    Division of Medical Oncology, Mount Sinai Medical Center, New York, NY 10029, USA
    Int J Oncol 24:187-92. 2004
    ..The potential of SFN, as an active dietary factor to inhibit initiation and post-initiation of prostate cancer carcinogenesis is discussed...
  40. ncbi request reprint Isolation and characterization of human umbilical cord mesenchymal stem cells with hematopoiesis-supportive function and other potentials
    Lu Lu Lü
    National Engineering Research Center of Cell Products, AmCellGene Co Ltd
    Haematologica 91:1017-26. 2006
    ..We isolated MSC from human full term umbilical cord tissues (UC). The biological characteristics of MSC derived from UC (UC-MSC) were further determined and compared with normal adult bone marrow-derived MSC (BM-MSC)...
  41. doi request reprint Severe imatinib-associated muscle edema in patients with chronic myelogenous leukemia and marked leukocytosis
    Sivamurthy Kyathari
    Leuk Lymphoma 49:1002-4. 2008
  42. ncbi request reprint p38 mitogen-activated protein kinase plays an inhibitory role in hepatic lipogenesis
    Yan Xiong
    Endocrine Biology Program, Center for Integrated Genomics, The Hamner Institutes for Health Sciences, Research Triangle Park, North Carolina 27709, USA
    J Biol Chem 282:4975-82. 2007
    ..Together, we have identified an inhibitory role for p38 in the transcription of central lipogenic genes, SREBPs, and PGC-1beta and hepatic lipogenesis...
  43. ncbi request reprint A geometric approach to determine association and coherence of the activation times of cell-cycling genes under differing experimental conditions
    Delong Liu
    Biostatistics Branch, MD A3 03, National Institute of Environmental Health Sciences, National Institutes of Health, PO Box 12233, Research Triangle Park, NC 27709, USA
    Bioinformatics 20:2521-8. 2004
    ..Our proposed methodology is illustrated by applying it to a HeLa cell-cycle gene-expression data...
  44. ncbi request reprint Acute myelogenous leukemia following irinotecan-based chemotherapy for adenocarcinoma of the small intestine
    Samir Patel
    Leuk Lymphoma 48:1032-3. 2007
  45. pmc Analysis of variation of amplitudes in cell cycle gene expression
    Delong Liu
    CIIT Ceters for Health Research, 6 Davis Drive, Research Triangle Park, NC 27709, USA
    Theor Biol Med Model 2:46. 2005
    ..We investigated whether different cell-arresting methods have impacts on the maximum expression levels (amplitudes) of a cell cycle related gene...